Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins

    Oramed Receives Patent Allowance in Israel and Australia for Platform
                   Technology in Oral Delivery of Proteins

PR Newswire

JERUSALEM, January 2, 2014

JERUSALEM, January 2, 2014 /PRNewswire/ --



Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that it has received
Notices of Allowance from the Israel and Australian Patent Offices. The patent
entitled, "Methods and Compositions for Oral Administrations of Proteins"
covers a core concept of the company's technology for the oral delivery of
drugs and vaccines currently delivered via injection. The allowance in Israel
marks the second from the Israel Patent Office in the past 30 days.
Additionally, this is Oramed's second Australian patent allowance, following
the grant of a different patent in May 2012. The patent has also been
approved in Japan, China, Russia, and New Zealand. 

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's Protein Oral Delivery (POD^[^TM^]) technology is
based on over 30 years of research by top research scientists
atJerusalem'sHadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on
patients with type 2 diabetes (T2DM) under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), with trials underway. Oramed is
also moving forward with clinical trials of ORMD-0801 for the treatment of
type 1 diabetes. The company's corporate and R&D headquarters are based
inJerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements:This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our clinical trials or revolutionizing the treatment of diabetes with
our products. These forward-looking statements and their implications are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.